Overview

Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis

Status:
Completed

Trial end date:
2003-12-01

Target enrollment:

Participant gender:

Summary

The objectives of this study were to demonstrate comparable safety and efficacy of Terconazole Vaginal Suppositories, 80 mg(Test Product) and Terconazole Vaginal Suppositories, 80 mg(Reference Product) in the treatment of subjects with vulvovaginal candidiasis in order to establish bioequivalence.

Phase:

N/A

Details

Lead Sponsor:

Padagis LLC
Perrigo Company

Treatments:

Terconazole